Takeda Pharmaceutical Shares Outstanding 2007-2019 | TAK

Takeda Pharmaceutical shares outstanding history from 2007 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Takeda Pharmaceutical shares outstanding for the quarter ending September 30, 2019 were 3.124B, a 100.26% increase year-over-year.
  • Takeda Pharmaceutical 2019 shares outstanding were 1.934B, a 22.9% increase from 2018.
  • Takeda Pharmaceutical 2018 shares outstanding were 1.573B, a 0.1% increase from 2017.
  • Takeda Pharmaceutical 2017 shares outstanding were 1.572B, a 0.29% decline from 2016.
Takeda Pharmaceutical Annual Shares Outstanding
(Millions of Shares)
2019 1,934
2018 1,573
2017 1,572
2016 1,576
2015 1,573
2014 1,581
2013 1,579
2012 1,579
2011 1,579
2010 1,579
2009 1,617
2008 1,697
2007 1,740
2006 1,772
Takeda Pharmaceutical Quarterly Shares Outstanding
(Millions of Shares)
Q2 2019 3,124
Q1 2019 3,111
Q3 2018 1,573
Q1 2018 1,564
Q1 2017 1,560
Q1 2016 1,564
Q1 2015 1,570
Q4 2015 1,574
Q3 2014 1,578
Q2 2014 1,572
Q1 2014 1,575
Q4 2014 1,578
Q3 2013 1,581
Q2 2013 1,578
Q1 2013 1,581
Q4 2013 1,580
Q3 2012 1,579
Q2 2012 1,579
Q1 2012 1,579
Q4 2012 1,579
Q3 2011 1,578
Q2 2011 1,582
Q4 2011 1,579
Q4 2010 1,579
Q2 2009 6
Q4 2009 1,588
Q4 2008 1,940
Q4 2007 1,716
Q4 2006 1,790
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $63.496B $18.875B
Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $56.165B 33.60
Astellas Pharma (ALPMY) Japan $31.345B 15.66
Eisai (ESALY) Japan $18.870B 36.39
Merck (MKGAF) Germany $15.276B 20.85
Grifols, S.A (GRFS) Spain $14.913B 19.03
UCB SA (UCBJF) Belgium $14.669B 0.00
Neurocrine Biosciences (NBIX) United States $10.411B 491.52
Ono Pharmaceutical (OPHLF) Japan $9.450B 20.20
IPSEN SA ADR (IPSEY) France $8.953B 0.00
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $8.638B 0.00
Ionis Pharmaceuticals (IONS) United States $8.244B 16.70
Jazz Pharmaceuticals (JAZZ) Ireland $7.843B 10.02
Sage Therapeutics (SAGE) United States $7.582B 0.00
Catalent (CTLT) United States $7.377B 30.01
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.214B 0.00
Orion OYJ (ORINY) Finland $5.849B 30.12
STADA ARZNEIMI (STDAF) Germany $5.375B 0.00
Hypermarcas (HYPMY) Brazil $5.134B 18.45
Arrowhead Pharmaceuticals (ARWR) United States $4.498B 103.13
United Therapeutics (UTHR) United States $3.968B 0.00
Nektar Therapeutics (NKTR) United States $3.457B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.363B 12.29
FibroGen (FGEN) United States $3.227B 94.85
Evotec AG (EVTCY) Germany $3.081B 50.42
PTC Therapeutics (PTCT) United States $2.693B 0.00
Portola Pharmaceuticals (PTLA) United States $2.117B 0.00
Xencor (XNCR) United States $2.041B 62.03
Tilray (TLRY) Canada $1.998B 0.00
Zogenix (ZGNX) United States $1.998B 0.00
Heron Therapeutics (HRTX) United States $1.943B 0.00
Corcept Therapeutics (CORT) United States $1.879B 22.83
Ironwood Pharmaceuticals (IRWD) United States $1.800B 57.40
Pacira Pharmaceuticals (PCRX) United States $1.791B 52.99
USANA Health Sciences (USNA) United States $1.560B 16.65
CLINIGEN GP (CLIGF) United Kingdom $1.244B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.232B 20.33
Radius Health (RDUS) United States $1.108B 0.00
Endo (ENDP) Ireland $1.027B 1.89
Theravance Biopharma (TBPH) Cayman Islands $1.013B 0.00
Karyopharm Therapeutics (KPTI) United States $0.980B 0.00
ArQule (ARQL) United States $0.951B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.938B 0.00
Aerie Pharmaceuticals (AERI) United States $0.877B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $0.823B 5.61
Organogenesis Holdings (ORGO) United States $0.758B 0.00
TherapeuticsMD (TXMD) United States $0.743B 0.00
Flexion Therapeutics (FLXN) United States $0.614B 0.00
Collegium Pharmaceutical (COLL) United States $0.607B 0.00
Translate Bio (TBIO) United States $0.565B 0.00
Concordia (CXRXF) Canada $0.552B 0.00
ChemoCentryx (CCXI) United States $0.513B 0.00
ImmunoGen (IMGN) United States $0.495B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.492B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.459B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.458B 55.50
Crinetics Pharmaceuticals (CRNX) United States $0.450B 0.00
OptiNose (OPTN) United States $0.433B 0.00
Dermira (DERM) United States $0.415B 0.00
Siga Technologies (SIGA) United States $0.402B 9.19
Akebia Therapeutics (AKBA) United States $0.400B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.392B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.389B 16.78
Recro Pharma (REPH) United States $0.389B 0.00
Indivior (INVVY) United States $0.387B 1.40
Ardelyx (ARDX) United States $0.386B 0.00
DURECT (DRRX) United States $0.373B 0.00
Innate Pharma SA (IPHYF) France $0.372B 0.00
Lannett Co Inc (LCI) United States $0.369B 4.29
Harpoon Therapeutics (HARP) United States $0.339B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.288B 0.00
GlycoMimetics (GLYC) United States $0.270B 0.00
Molecular Templates (MTEM) United States $0.268B 0.00
Rafael Holdings (RFL) United States $0.258B 0.00
Xeris Pharmaceuticals (XERS) United States $0.222B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.209B 0.00
KalVista Pharmaceuticals (KALV) United States $0.197B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.193B 0.00
Nature's Sunshine Products (NATR) United States $0.188B 32.37
Calithera Biosciences (CALA) United States $0.188B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.187B 0.00
Jounce Therapeutics (JNCE) United States $0.174B 2.33
Matinas Biopharma Holdings (MTNB) United States $0.169B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.163B 0.00
Taiwan Liposome (TLC) Taiwan $0.163B 0.00
Concert Pharmaceuticals (CNCE) United States $0.160B 0.00
Aquestive Therapeutics (AQST) United States $0.150B 0.00
Redhill Biopharma (RDHL) Israel $0.137B 0.00
MEI Pharma (MEIP) United States $0.135B 0.00
Ocular Therapeutix (OCUL) United States $0.135B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.134B 0.00
CV Sciences (CVSI) United States $0.134B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.131B 0.00
IMV INC (IMV) Canada $0.126B 0.00
CannTrust Holdings (CTST) Canada $0.124B 0.00
Cardiome Pharma (CORV) Canada $0.115B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.108B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.100B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.092B 0.00
Majesco Entertainment (PTE) United States $0.089B 0.00
MediWound (MDWD) Israel $0.083B 0.00
Neos Therapeutics (NEOS) United States $0.077B 0.00
Aclaris Therapeutics (ACRS) United States $0.076B 0.00
Otonomy (OTIC) United States $0.075B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.074B 22.05
Generex Biotechnology (GNBT) United States $0.072B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.067B 0.00
SCYNEXIS (SCYX) United States $0.066B 0.00
Champions Oncology (CSBR) United States $0.063B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.062B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.062B 0.00
Natural Alternatives (NAII) United States $0.061B 15.18
Genocea Biosciences (GNCA) United States $0.059B 0.00
Medicure (MCUJF) Canada $0.057B 0.00
Infinity Pharmaceuticals (INFI) United States $0.056B 0.00
Pharmaxis (PXSLY) Australia $0.055B 0.00
RENEURON GP (RNUGF) United Kingdom $0.054B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.053B 0.00
Novan (NOVN) United States $0.053B 0.00
AgeX Therapeutics (AGE) United States $0.052B 0.00
IntelGenx Technologies (IGXT) Canada $0.051B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.049B 0.00
Capnia (SLNO) United States $0.049B 0.00
Nivalis Therapeutics (ALPN) United States $0.048B 0.00
ElectroCore (ECOR) United States $0.047B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.046B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.044B 0.00
CTI BioPharma (CTIC) United States $0.042B 0.00
Forward Pharma (FWP) Denmark $0.041B 0.00
Mannatechorporated (MTEX) United States $0.036B 0.00
Opexa Therapeutics (ACER) United States $0.034B 0.00
Iterum Therapeutics (ITRM) Ireland $0.031B 0.00
Bio-Path Holdings (BPTH) United States $0.031B 0.00
Jaguar Animal Health (JAGX) United States $0.031B 0.00
India Globalization Capital (IGC) United States $0.031B 0.00
Mast Therapeutics (SVRA) United States $0.030B 0.00
Biomerica (BMRA) United States $0.029B 0.00
IsoRay (ISR) United States $0.026B 0.00
PharmAthene (ALT) United States $0.025B 0.00
China SXT Pharmaceuticals (SXTC) China $0.023B 0.00
Melinta Therapeutics (MLNT) United States $0.023B 0.00
ProPhase Labs (PRPH) United States $0.021B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.017B 0.00
Heat Biologics (HTBX) United States $0.015B 0.00
Flex Pharma (SLRX) United States $0.015B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.014B 0.00
Cyanotech (CYAN) United States $0.014B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.014B 0.00
Shineco (TYHT) China $0.014B 0.00
Regulus Therapeutics (RGLS) United States $0.013B 0.00
Lipocine (LPCN) United States $0.010B 0.00
HANCOCK JAFFE (HJLI) United States $0.010B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.008B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.007B 0.00
Vical (BBI) United States $0.007B 0.00
Achieve Life Sciences (ACHV) United States $0.007B 0.00
RXi Pharmaceuticals (PHIO) United States $0.005B 0.00
VAXART, INC (VXRT) United States $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.004B 0.00
Can-Fite Biopharma (CANF) Israel $0.003B 0.00
Midatech Pharma (MTP) United Kingdom $0.002B 0.00
Onconova Therapeutics (ONTX) United States $0.002B 0.00
Hemispherx BioPharma (AIM) United States $0.001B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.001B 0.00
Advanced Accelerator Applications S.A (AAAP) France $0.000B 0.00